INH is one of the first line anti-tuberculosis drugs (11), and its bactericidal mechanism is mainly through acting on its target enoyl acyl carrier protein reductase (InhA), and InhA is an enzyme involved mainly in fatty acid synthesis and mycolic acid biosynthesis (12, 31). This evidence concerns the gene FASN and tuberculosis.